Clinical Trials Related to Mantle Cell Lymphoma

Related studies linked through entity extraction aliases.

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE3

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Status: COMPLETED
Phase: PHASE2

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Status: TERMINATED
Phase: PHASE2/PHASE3

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Status: COMPLETED
Phase: PHASE1/PHASE2

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE1/PHASE2

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE2

Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

Status: COMPLETED
Phase: PHASE2

Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)

Status: COMPLETED
Phase: PHASE2

Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE2

Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE2

Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE2

VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE1/PHASE2

Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma

Status: WITHDRAWN
Phase: N/A

Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE2

Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)

Status: COMPLETED
Phase: PHASE2

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE1/PHASE2

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Status: COMPLETED
Phase: PHASE2

Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

Status: COMPLETED
Phase: PHASE1

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Status: COMPLETED
Phase: PHASE1/PHASE2

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE2